Overview
- The paper, published Monday, Aug 3, 2026, by researchers at the Weizmann Institute and collaborators combined cell and mouse experiments with about 20 years of anonymized Israeli health records covering roughly five million people.
- In lab tests sildenafil disrupted how cancer cells access and use cholesterol, a change that reduced cell migration in culture and lowered metastatic growth in mice.
- A retrospective analysis found that men who used sildenafil before a cancer diagnosis had better overall survival, and the survival signal was larger among those who also took statins.
- Authors and independent experts stress the evidence is associative and limited because the human data are observational, mostly reflect pre‑diagnosis use in men, and cannot prove that sildenafil caused the better outcomes.
- Researchers propose targeted follow‑up work and randomized clinical trials to test whether sildenafil alone or with statins can safely slow metastasis and to define which cancers, doses, timing, and patient groups might benefit.